Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1991317 | 1.00 | PDE2A (0.41) | PDE2ATRPV1NR1H4 | |
| SCHEMBL1988302 | 0.93 | PDE2A (0.44) | PDE2A | |
| SCHEMBL12604677 | 0.93 | PDE2A (0.44) | PDE2A | |
| SCHEMBL12605003 | 0.91 | KCNQ3 (0.38) | PDE2ATRPV1 | |
| SCHEMBL1660851 | 0.91 | KCNQ3 (0.38) | PDE2ATRPV1 | |
| SCHEMBL1986283 | 0.90 | PDE2A (0.39) | PDE2ATRPV1 | |
| SCHEMBL12603593 | 0.90 | PDE2A (0.39) | PDE2ATRPV1 | |
| SCHEMBL12563263 | 0.87 | PDE2A (0.47) | PDE2ANR1H4 | |
| SCHEMBL1988183 | 0.87 | PDE2A (0.40) | PDE2A | |
| SCHEMBL12604672 | 0.86 | KCNQ3 (0.42) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307394-B1 | SULPHONAMIDES AS VANILLOID RECEPTOR ANTAGONIST | AMOREPACIFIC CORP (KR) | 2012-09-26 | — | — | EP | disclosed |
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2011-06-23 | — | — | US | disclosed |
| WO-2010002209-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | PDE2A 1939/4885TRPV1 1/4885NR1H4 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.